HICOGEN employs a synergistic, multi-targeted approach to male sexual function, leveraging vascular, neuroendocrine, and adaptogenic pathways. Eurycoma longifolia is central to the endocrine modulation, optimizing systemic testosterone availability to support key physiological functions.
A double-blind, parallel-group, randomized placebo-controlled trial, titled “Vitamin D Supplementation and Improvement in Insomnia Symptoms Among Malaysian Women With Vitamin D Deficiency: Protocol for a Randomized Controlled Trial,” aims to evaluate the efficacy of weekly vitamin D₃ supplementation (50,000 IU/wk) versus placebo over 9 weeks. The study targets Malaysian women aged 19-50 with serum 25(OH)D levels <20 ng/mL and insomnia symptoms. Primary outcomes include insomnia severity (Insomnia Severity Index), sleep quality (Pittsburgh Sleep Quality Index), and sleep efficiency (actigraphy). Secondary outcomes involve daytime sleepiness (Epworth Sleepiness Scale) and functional outcomes (Functional Outcomes of Sleep Questionnaire). Recruitment commenced in December 2023, with an anticipated conclusion in December 2026. As of July 2026, 42 participants have been screened, 33 enrolled, 22 completed, 4 are in the intervention phase, and 1 withdrew due to loss of contact. The study explores vitamin D's potential role as a supplementary approach for insomnia management.
HICOGEN’s formulation, including Eurycoma longifolia, is precisely integrated to provide targeted benefits for approved indications such as Erectile Dysfunction (Mild to Moderate), Hypoactive Sexual Desire Disorder (HSDD), Male Infertility & Oligospermia, and Sexual Asthenia & Performance Anxiety. While general nutritional studies may highlight broader health benefits, HICOGEN focuses on specific pharmacological pathways to address male sexual health, distinguishing its clinical application. The comprehensive profile of HICOGEN mandates caution in patients with hypersensitivity to any botanical extracts. Due to the androgen-modulating effects of Eurycoma longifolia, concurrent use with hormone therapies requires careful clinical assessment. The overall formulation is generally well-tolerated, with rare mild adverse reactions such as insomnia, gastrointestinal upset, or transient flushing. Adherence to prescribing guidelines ensures optimal patient safety and efficacy within the approved indications.
Q: How does HICOGEN, with Eurycoma longifolia, specifically address approved indications for male sexual dysfunction, distinguishing its approach from general health interventions?
A: HICOGEN’s efficacy stems from a targeted, multi-pathway pharmacological design. Eurycoma longifolia directly enhances free testosterone, a critical factor for improving penile hemodynamics in erectile dysfunction, restoring diminished libido in HSDD, and supporting spermatogenesis for male infertility. This focused endocrine modulation, combined with HICOGEN’s vascular and neuro-adaptogenic components, provides a precise intervention for specific male sexual health conditions, unlike broad nutritional supplementation which may lack such targeted mechanisms.
Q: What are the key safety considerations for HICOGEN, particularly concerning the endocrine-modulating effects of Eurycoma longifolia?
A: Patients should be screened for hypersensitivity to any HICOGEN components. Due to Eurycoma longifolia’s influence on androgen levels, caution is advised for individuals undergoing hormone therapies, necessitating close clinical monitoring. While generally well-tolerated, rare adverse events such as mild insomnia (if taken late), mild gastrointestinal upset, or transient flushing may occur, which should be managed symptomatically. The absolute contraindication remains hypersensitivity to any botanical extract in the formulation.
